Clinical Trials Browser

Observational × Lung Neoplasms × durvalumab × Clear all

NCT04364776 2023-09-28

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Lung Neoplasms

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT04285866 2022-06-07

S-REAL

Lung Neoplasms, Small Cell Lung Carcinoma